Nicholas A. Jessop

TL;DR: Findings from a series of lung cancer patients with acquired resistance to the ALK TKI crizotinib reinforce the need to tailor therapeutic strategies to the specific underlying drug resistance mechanisms in the tumors to improve clinical outcomes.

TL;DR: In this article, the authors studied EGFR blockade in colorectal cancer to assess whether tissue and liquid biopsies can be integrated with radiological imaging to monitor the impact of individual oncogenic alterations on lesion-specific responses.

TL;DR: Specific ALK variants may be associated with the development of ALK resistance mutations, particularly G1202R, and provide a molecular link between variant and clinical outcome, and represent a potentially important factor in the selection of next-generation ALK inhibitors.

TL;DR: BRAF-mutant NSCLC is a heterogeneous disease that encompasses 3 distinct functional classes that have more aggressive clinical features leading to less favorable outcomes and the distinct biological characteristics of class II and III tumors suggest that class-specific therapies may be necessary to effectively target these molecular subsets.

TL;DR: Clinical outcomes are poor in this molecular subgroup of patients with BRG1-deficient NSCLC who received first-line platinum doublet chemotherapy or chemotherapy plus immunotherapy, highlighting the importance of developing novel strategies to target unique vulnerabilities associated with the BRG 1-deficiency state.